Rock Creek Group LP Makes New Investment in Cellebrite DI Ltd. $CLBT

Rock Creek Group LP acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 150,000 shares of the company’s stock, valued at approximately $2,704,000. Cellebrite DI accounts for 0.3% of Rock Creek Group LP’s holdings, making the stock its 27th largest holding.

Several other large investors have also recently added to or reduced their stakes in CLBT. Geode Capital Management LLC increased its position in shares of Cellebrite DI by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 371,739 shares of the company’s stock worth $6,700,000 after purchasing an additional 31,855 shares during the period. King Luther Capital Management Corp increased its position in shares of Cellebrite DI by 17.6% in the fourth quarter. King Luther Capital Management Corp now owns 354,184 shares of the company’s stock worth $6,386,000 after purchasing an additional 52,945 shares during the period. Legal & General Group Plc increased its position in shares of Cellebrite DI by 6.3% in the fourth quarter. Legal & General Group Plc now owns 227,797 shares of the company’s stock worth $4,107,000 after purchasing an additional 13,563 shares during the period. TimesSquare Capital Management LLC increased its position in shares of Cellebrite DI by 18.3% in the fourth quarter. TimesSquare Capital Management LLC now owns 715,992 shares of the company’s stock worth $12,909,000 after purchasing an additional 110,630 shares during the period. Finally, ProShare Advisors LLC bought a new position in shares of Cellebrite DI in the fourth quarter worth $229,000. Institutional investors own 45.88% of the company’s stock.

Analysts Set New Price Targets

CLBT has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. DA Davidson initiated coverage on Cellebrite DI in a research report on Wednesday. They issued a “buy” rating and a $20.00 price target on the stock. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Finally, Needham & Company LLC decreased their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Cellebrite DI currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Cellebrite DI Stock Up 11.6%

NASDAQ:CLBT opened at $14.73 on Friday. The stock’s 50-day simple moving average is $13.27 and its 200 day simple moving average is $15.29. The firm has a market capitalization of $3.67 billion, a PE ratio of 52.61, a price-to-earnings-growth ratio of 1.58 and a beta of 1.15. Cellebrite DI Ltd. has a twelve month low of $11.02 and a twelve month high of $19.98.

Insiders Place Their Bets

In related news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the sale, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold 13,269 shares of company stock valued at $169,592 over the last quarter. Company insiders own 5.70% of the company’s stock.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.